[go: up one dir, main page]

WO1997031268A1 - Bande chromatographique ayant des zones de detection et de controle orientees parallelement a la direction de l'ecoulement - Google Patents

Bande chromatographique ayant des zones de detection et de controle orientees parallelement a la direction de l'ecoulement Download PDF

Info

Publication number
WO1997031268A1
WO1997031268A1 PCT/US1997/002159 US9702159W WO9731268A1 WO 1997031268 A1 WO1997031268 A1 WO 1997031268A1 US 9702159 W US9702159 W US 9702159W WO 9731268 A1 WO9731268 A1 WO 9731268A1
Authority
WO
WIPO (PCT)
Prior art keywords
strip
analyte
sample
test
antibody
Prior art date
Application number
PCT/US1997/002159
Other languages
English (en)
Inventor
David Bernstein
Original Assignee
Universal Healthwatch, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universal Healthwatch, Inc. filed Critical Universal Healthwatch, Inc.
Priority to AU20502/97A priority Critical patent/AU2050297A/en
Publication of WO1997031268A1 publication Critical patent/WO1997031268A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow

Definitions

  • the present invention relates to gualitative diagnostic test strip devices incorporating a visually detectable result format which generates or develops an image to indicate a positive test result for analyte and another image to indicate a procedural control for analyte. More particularly, it relates to improved diagnostic test strip devices wherein the reagents responsible for the development of the test result and control images are oriented substantially parallel to the flow of reagent fluid within said strip.
  • Diagnostic assays have become an indispensable means for detecting analytes in test samples, and for the most part the medical profession has used highly automated clinical laboratories and sophisticated equipment for these determinations. There is, however, an expanding need for having analytical capabilities in doctors' offices, in the home, and in the field where electricity and other semblances of a laboratory are unavailable. Together with the diagnosis of disease or physiological conditions or disorders, there is a growing need to monitor the effects of drug therapy and chronic illness, to detect the use of drugs of abuse and to detect the presence of contaminants.
  • the dipstick generally uses a plastic strip with a reagent-containing matrix layered thereon.
  • a test sample is applied to the device, and the presence of the analyte is indicated by a visually detectable signal such as a color-forming reaction.
  • the flow-through device generally uses a porous material with a reagent containing matrix layered thereon or incorporated therein.
  • Test sample is applied to and flows through the porous material, and analyte in the sample reacts with the reagent(s) to produce a detectable signal on the porous material.
  • Hochstrasser U.S. Pat. No. 4,059,407 discloses a dipstick device which can be immersed in a biological fluid to semi quantitate analyte in the fluid. Semi quantitation of the analyte is accomplished by using a series of reagent containing pads wherein each pad in the series will produce a detectable color (i.e., a positive result) in the presence of an increasing amount of analyte. Also of interest in the area of dipstick devices are U.S. Pat. Nos.
  • a chromatographic strip test device including an absorbent strip having an end portion for contacting a test solution.
  • a test region is spaced from the end portion and contains a spot of immobilized antibody specific for analyte, for example.
  • the strip also includes an unbound label capture zone including immobilized analyte analog.
  • a test solution is prepared by mixing a sample with a first specific binding pair member, for example, a labelled antibody conjugate for analyte. After incubation, the test solution contains analyte/antibody label complexes and labelled antibody conjugate which is unbound to sample analyte.
  • test solution is contacted to the end of the strip which causes the test solution to migrate up the strip towards the test region.
  • any excess or unbound label in the test solution binds to the analyte-analog at this zone and is prevented f rom further migration along the strip.
  • analyte/antibody-label complexes are present in the test solution, these complexes will continue to migrate to the test region where they are immobilized into a sandwich complex by the immobilized antibody located in this zone.
  • the end portion of the strip may be contacted with other signal-system reagents which migrate up the strip to the test region and react with the label present in the sandwich complexes to generate a detectible signal.
  • the presence or absence of a signal at the test region indicates the presence or absence of analyte in the sample.
  • the device and method require the end user to mix and incubate the test solution and to add the signal-system reagents and the test solution in the proper sequence.
  • the device has no procedural controls built in which will verify to the end user that all of the reagents are functioning properly and that the proper steps have been followed to indicate a reliable result.
  • Diagnostic test strip devices are described in U.S. Patent Nos. 5,075,078 and 4,916,056, which include a test region having a capture reagent, typically an antibody, specific for sample analyte located thereat.
  • a conjugate pad is located adjacent to the test strip at an upstream sample entry location.
  • the conjugate pad includes labelled antibody and any other assay reagents which may be desirable or required.
  • the end user simply adds an amount of the sample, for example a bodily fluid such as blood, serum or urine, to a sample entry port.
  • the sample migrates through the conjugate pad liberating and mixing sample fluids with the other assay reagents provided in the conjugate pad.
  • the combined fluids migrate to the chromatographic strip and are drawn through the testing zone whereupon a signal may be developed.
  • the devices also contain an end of test region including a p H indicator dye located at the downstream end of the strip which changes color upon contact with the test fluids to indicate that the test is over and that no further waiting is needed to obtain the test result.
  • a visually-detectable result format which generates or develops the image of a plus sign, i.e. a + sign, to indicate a positive or yes result and a minus sign, i.e. a - sign, to indicate a negative or no result are also known. See, for example, FIG lb.
  • the image formed can appear as a spot located at the leading edge of the procedural control bar spaced from a darkened line of signal along the upstream leading edge of the patient bar adjacent an ill-defined trailing shadow area.
  • An indistinct image which does not resemble a plus sign results. This image can easily be misinterpreted as a minus sign.
  • test strip device capable of consistently providing a strong, fully defined test result image which is inherently clear, leaving no room for misinterpretation of results is still desirable or required.
  • the present inventors have discovered that shortcomings of the prior art devices may be overcome by orienting the procedural control area and one or more sample test areas on the test strip parallel to the flow of reagents through the porous strip. In this way, the migrating fluid will contact the control area and test area(s) substantially equally.
  • the user of the device can monitor the results with confidence that strong, well-defined images will be provided depending upon the presence or absence of analyte.
  • the test strip device includes a chromatographic strip substrate having a length and width capable of conveying fluids in a fluid flow direction generally parallel to the length of the strip.
  • the strip includes a sample contact region in which a fluid sample and other assay reagents may be contacted with said strip.
  • the strip also includes a testing region disposed on said strip at a downstream location from the sample contact region.
  • the testing region includes a sample test area defined by a first capture reagent specific for the analyte being tested, immobilized on the strip testing region.
  • a procedural control area defined by a second capture reagent specific for an assay label immobilized on the strip test region is also provided in the testing region.
  • the control and test areas may be of any shape (e.g., a generally rectangular configuration), although substantially similar shapes are preferred.
  • the chromatographic strip substrate comprises nitrocellulose.
  • the first capture reagent defining the sample test area comprises immobilized antibody specific for the sample analyte being determined.
  • the second capture reagent defining the procedural control area comprises immobilized analyte.
  • the test strip device includes an application pad adjacent the sample contact region of the strip and in fluid flow contact therewith. The application pad receives the test sample. It comprises a porous substrate and a diffusible label.
  • the label conjugate comprises an antibody conjugated to a colloid gold and/or colloidal selenium label material.
  • the label conjugate comprises a monoclonal antibody from a first species specific for the analyte being tested, conjugated to a labeling substance.
  • the second capture reagent comprises an antibody from a second species which immunologically reacts with the monoclonal antibody of the first species.
  • test area and the control area are equally sized and are positioned equidistantly from the sample contact region.
  • test area and the control area are positioned above an absorbent pad. Fluid that moves through the strip is channeled through these areas. This embodiment can provide greater sensitivity by virtue of increasing the proportion of fluid that passes over the test area.
  • the chromatographic test strip devices of this invention provide sharp clearly defined test result images which unequivocally indicate a positive or negative test result.
  • the assays are virtually self-performing in that they require the user to simply add a few drops of sample fluid to the sample entry region and wait a few minutes for an easily understood test result to be obtained. Rapid, accurate and relatively inexpensive immuno-diagnostic tests may be provided to physicians offices or to patients directly in this format.
  • FIGS. la and lb are perspective views of prior art chromatographic strip test devices
  • FIGS. 2a, 2b, 2c and 2d are top views of chromatographic test strip devices in accordance with this invention.
  • FIG. 3 is a perspective view of a chromatographic test strip device in accordance with this invention in operation. Detailed Description of t ⁇ ⁇ >r*f ⁇ r ⁇ ffilfrodlm ⁇ nts Referring now to FIGS. 2a, 2b, 2c and 2d, exemplary chromatographic strip binding assay devices of the present invention are illustrated.
  • the devices may be constructed in accordance with well-known methods of the prior art. See, for example, U.S. Patent No. 5,075,078, which is incorporated herein by reference in its entirety. Constructions other than those of the '078 patent readily will be apparent to the skilled artisan. Accordingly, the detailed construction of such strip assays will not be repeated herein.
  • FIG. 2a illustrates a strip binding assay in which sample testing area 22 and procedural control area 24 are located substantially parallel to the length of strip 20.
  • the areas are substantially rectangular, but most other shapes are acceptable. Also, while both areas are illustrated as substantially the same shape, they can be different shapes as shown in FIG. 2b.
  • sample testing area 32 and procedural control area 34 are located substantially equidistant along the length of strip 30. As shown in the drawing, sample testing area 32 is substantially rectangular and procedural control area 34 is substantially circular.
  • sample testing areas 42 and 43, and procedural control areas 44 and 45 are located substantially parallel to the length of strip 40. As shown in the drawing, the sample testing areas and procedural control areas are of different shapes.
  • sample test area 52 and procedural control area
  • Absorbent pad 56 is positioned below test area 52 and control area 54. During use, absorbent pad 56 channels fluid through test area 52 and control area 54.
  • the increase in flow of reagent is substantial, i.e. at least 50% more sample contacts the test area compared to the same strip that does not channel the flow of reagent.
  • the channeling of flow results in improvement to sensitivity because a greater proportion of fluid that passes along the strip contacts the test area.
  • test area is positioned parallel to the flow of reagents through the strip.
  • parallel is meant that the test area is longer than it is wide with respect to the direction of fluid movement during operation of the strip.
  • test and control areas can be of any shape, in general the shapes should be relatively uncomplicated so as to avoid the problems of the prior art such as localized depletion of label conjugate. Hence, substantially circular or rectangular shapes will be commonly used.
  • test and control areas will be located closely together, also to avoid problems such as localized depletion of label conjugate.
  • fluids are wicked or permitted to migrate along strip 60 parallel to the length of the strip in the direction shown by arrow a toward sample testing area 62 and procedural control area 64.
  • the downstream end of strip 60 has a pH indicator dye 68 coated or deposited thereon.
  • the pH indicator dye 68 changes color when contacted by migrating sample and testing fluids.
  • the test device of this invention may comprise a test for early detection of human pregnancy.
  • the test device performs an immunoassay for detecting an elevated level of human chorionic gonadotropin (hCG) , a hormone which is present in patient urine samples at elevated levels during early stages of pregnancy.
  • hCG human chorionic gonadotropin
  • the device of this invention includes a sample test area defined by an immobilized anti-Beta HCG antibody.
  • the label conjugate employed comprises for example an anti-Beta HCG antibody conjugated to a colloidal gold and/or colloidal selenium label.
  • a preferred assay employing colloidal gold and colloidal selenium labels is disclosed in application serial no. , filed December 13, 1995 (Attorney Docket No. 73294/103), the contents of which are expressly incorporated herein by reference.
  • the procedural control area may comprise an immobilized hCG/anti-Beta hCG complex.
  • a doctor or a patient adds a few drops of patient urine sample into the sample fluid entry aperture.
  • the sample wets the application pad, and the selenium colloid conjugate, for example, in the pad migrates with the sample fluid along the strip and through the testing region. If the sample does not contain hCG the reddish-pink colored selenium conjugate binds only to the procedural control area of the test region which forms the visib l e image of the area. This clearly and unequivocally indicates that no hCG is present in the sample and that the test is functioning properly.
  • patient hCG binds to the anti-hCG antibody on the label conjugate to form a labelled analyte complex which then binds to the anti-hCG antibody in the sample test area forming a reddish-pink area therein.
  • the visible sign clearly and unequivocally indicates that the patient is pregnant. The patient or physician can obtain a reliable diagnosis of whether the patient is pregnant or not in less than five minutes.
  • the label conjugate comprises a monoclonal antibody from a first species conjugated to the labelling substance.
  • the procedural control area no longer includes an immobilized analyte but instead includes an immobilized antibody from a second species which is specific for the monoclonal antibody in the label conjugate from the first species.
  • the label conjugate may comprise a mouse monoclonal anti hCG selenium conjugate.
  • the procedural control area capture reagent may comprise a specific anti mouse IgG antibody immobilized to the strip.
  • the development of a visible signal at the procedural control area indicates that the mouse anti hCG selenium conjugate has migrated past the procedural control area and been bound by the anti-mouse capture reagent.
  • test sample which can be a liquid which is used directly as obtained from the source, or which has been pretreated in a variety of ways so as to modify its character
  • an application pad See for example, the '078 patent discussed above.
  • other means can be used to provide a measured or unmeasured quantity of sample to the device.
  • the sample passes through the application pad, where it contacts one or more reagents involved in producing the assay reaction, to the chromatographic material through which the test sample will wick and in which it will encounter one or more additional reagents involved in producing the detectable signal.
  • the test sample can be derived from any desired source, such as a physiological fluid, for example, blood, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, amniotic fluid or the like.
  • the fluid can be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, or the like; methods of treatment can also involve separation, filtration, distillation, concentration, inactivation of interfering components, and the addition of reagents.
  • physiological fluids other liquid samples such as water, food products and the like can be used.
  • a solid can be used once it is modified to form a liquid medium.
  • the present invention is particularly advantageous in that it combines several elements to form a novel assay device with which a one-step assay can be performed.
  • the novel device simplifies the assay protocols by decreasing the number of manual steps required for its use, thereby reducing the risk of errors during use.
  • the combination of elements in the present invention also enables the use of predetermined amounts of reagents incorporated within the device, thereby avoiding the need for reagent measurements and additions by the user.
  • the reagents are situated in the device in such a way as to make the assay substantially self-performing and to facilitate the detection and quantitation of the assay results. Definitions
  • a “specific binding member”, as used herein, is a member of a specific binding pair, i.e., two different molecules wherein one of the molecules through chemical or physical means specifically binds to the second molecule.
  • other specific binding pairs include, as examples without limitation, biotin and avidin, carbohydrates and lectins, complementary nucleotide sequences such as the probe and capture nucleic acids used in hybridization reactions with a target nucleic acid sequence as the analyte, complementary peptide sequences, effector and receptor molecules, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, enzyme substrates and enzymes, a peptide sequence and an antibody specific for the sequence or the entire protein, and the like.
  • specific binding pairs can include members that are analogs of the original specific binding member, for example an analyte-analog.
  • the specific binding member is an immunoreactant it can be, for example, an antibody, antigen, hapten, or complex thereof, and if an antibody is used, it can be a monoclonal or polyclonal antibody, a recombinant protein or antibody, a mixture(s) or fragment(s) thereof, as well as a mixture of an antibody and other specific binding members.
  • the details of the preparation of such antibodies and their suitability for use as specific binding members are well known to those skilled in the art.
  • Immunochromatography encompasses both sandwich and competitive immunoassay techniques.
  • an “analyte”, as used herein, is the compound or composition to be detected or measured in the test sample.
  • the analyte will have at least one epitope or binding site for which there exists a naturally occurring, complementary specific binding member or for which a specific binding member can be prepared.
  • “Analyte” also includes any antigenic substances, haptens, antibodies, and combinations thereof.
  • the analyte of interest in an assay can be, for example, a protein, a peptide, an amino acid, a nucleic acid, a hormone, a steroid, a vitamin, a pathogenic microorganism for which polyclonal and/or monoclonal antibodies can be produced, a natural or synthetic chemical substance, a contaminant, a drug including those administered for therapeutic purposes as well as those administered for illicit purposes, and metabolites of or antibodies to any of the above substances.
  • the hormones which are suitable as analytes for this invention are the following: thyroid stimulating hormone (TSH) , human chorionic gonadotropin (hCG) , luteinizing hormone ( H) and follicle stimulating hormone (FSH)'.
  • Pathogenic microorganisms suitable for analysis by the present invention include those microorganisms disclosed in U.S. Pat. No. 4,366,241, which is herein incorporated by reference. Illustrative of some of these microorganisms are those associated with urinary tract infections, such as Streptococcus pyogenes, Streptococcus salivarus, Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Proteus mirabilis and the like.
  • the microorganisms, when assayed by the present invention may be intact, lysed, ground or otherwise fragmented and the resulting composition or portion thereof assayed. Preferably, the microorganisms are assayed intact.
  • analyte-analog refers to a substance which cross-reacts with an analyte-specific binding member, although it may do so to a greater or a lesser extent than does the analyte self.
  • the analyte-analog can include a modified analyte as we_i as a fragmented or synthetic portion of the analyte molecule so long as the analyte-analog has at least one epitopic site in common with the analyte of interest.
  • Label as used herein, is any substance which is attached to a specific binding member and which is capable of producing a signal that is detectable by visual or instrumental means.
  • suitable labels for use in the present invention can include chromogens, catalysts, fluorescent compounds, chemiluminescent compounds, radioactive labels, direct visual labels including colloidal metallic and non-metallic particles, dye particles, enzymes or substrates, or organic polymer latex particles, liposomes or other vesicles containing signal producing substances, and the like.
  • enzymes suitable for use as labels are disclosed in U.S. Pat. No. 4,275,149, columns 19-23, herein incorporated by reference.
  • a particularly preferred enzyme/substrate signal producing system useful in the present invention is the enzyme alkaline phosphatase wherein the substrate used is nitro blue tetrazolium 5-bromo-4-chloro-3-indolyl phosphate or a derivative or analog thereof.
  • the label can be a fluorescent compound where no enzymatic manipulation of the label is required to produce a detectable signal. Fluorescent molecules such as fluorescein, phycobiliprotein, rhodamine and their derivatives and analogs are suitable for use as labels in this reaction.
  • a visually detectable, colored particle can be used as the label component of the indicator reagent, thereby providing for a direct colored readout of the presence of concentration of the analyte in the sample without the need for further signal producing reagents.
  • Materials for use as the colored particles are colloidal metals, such as gold, and dye particles as disclosed in U.S. Pat. Nos. 4,313,734 and 4,373,932.
  • the preparation and use of non-metallic colloids, such as colloidal selenium particles, are disclosed in U.S. Pat. No. 4,954,452.
  • Organic polymer latex particles for use as labels are known.
  • a “signal producing component”, as used herein, refers to any substance capable of reacting with another assay reagent or the analyte to produce a reaction product or signal that indicates the presence of the analyte and that is detectable by visual or instrumental means.
  • Signal production system refers to the group of assay reagents that are needed to produce the desired reaction product or signal.
  • one or more signal producing components can be used to react with a label and generate the detectable signal, i.e., when the label is an enzyme, amplification of the detectable signal is obtained by reacting the enzyme with one or more substrates or additional enzymes to produce a detectable reaction product.
  • an "ancillary specific binding member”, as used herein, refers to any member of a specific binding pair which is used in the assay in addition to the specific binding members of the capture reagent and the indicator reagent and which becomes a part of the final binding complex.
  • One or more ancillary specific binding members can be used in an assay.
  • an ancillary specific binding member can be capable of binding the analyte, as well as a second specific binding member to which the analyte itself could not attach.
  • binding assays involve the specific binding of the analyte and/or an indicator reagent (comprising a label attached to a specific binding member) to a capture reagent (comprising a second specific binding member) which immobilizes the analyte and/or indicator reagent on a chromatographic material or which at least slows the migration of the analyte or indicator reagent through the chromatographic material.
  • the labe- as described above, enables the indicator reagent to produce a detectable signal that is related to the amount of analyte in the test sample.
  • the specific binding member component of the indicator reagent enables the indirect binding of the label to the analyte, to an ancillary specific binding member or to the capture reagent.
  • a particular label is not critical, but the label will be capable of generating a detectable signal either by itself, such as a visually detectable signal generated by colored organic polymer latex particles, or in conjunction with one or more additional signal producing components, such as an enzyme/substrate signal producing system.
  • additional signal producing components such as an enzyme/substrate signal producing system.
  • indicator reagents can be formed by varying either the label or the specific binding member, it will be appreciated by one skilled in the art that the choice involves consideration of the analyte to be detected and the desired means of detection.
  • the capture reagent in a binding assay, is used to facilitate the observation of the detectable signal of substantially separating the analyte and/or the indicator reagent from other assay reagents and the remaining components of the test sample.
  • the capture reagent of the present invention is a specific binding member, such as those described above.
  • the capture reagent is immobilized on the chromatographic material to form a "capture situs", i.e., that region of the chromatographic material having one or more capture reagents non-diffusively attached thereto.
  • the application pad if used in the assay, is in fluid flow contact with one end of the chromatographic material, referred to as the proximal end, such that the test sample can pass or migrate from the application pad to the chromatographic material; fluid flow contact can include physical contact of the application pad to the chromatographic material as well as the separation of the pad from the chromatographic strip by an intervening space or additional material which still allows fluid flow between the pad and the strip. Substantially all of the application pad can overlap the chromatographic material to enable the test sample to pass through substantially any part of the application pad to the proximal end of the strip of chromatographic material. Alternatively, only a portion of the application pad might be in fluid flow contact with the chromatographic material.
  • the application pad can be any material which can transfer the test sample to the chromatographic material and which can absorb a volume of test sample that is equal to or greater than the total volume capacity of the chromatographic material.
  • nitrocellulose porous polyethylene frit or pads and glass fiber filter paper.
  • the material must also be chosen for its compatibility with the analyte and assay reagents, for example, glass fiber filter paper was found to be the preferred application pad material for use in a human chorionic gonadotropin (hCG) assay device.
  • hCG human chorionic gonadotropin
  • the application pad contains one or more assay reagents either diffusively or non-diffusively attached thereto.
  • Reagents which can be contained in the application pad include, but are not limited to, indicator reagents, ancillary specific binding members, and any signal producing system components needed to produce a detectable signal.
  • an indicator reagent be diffusively attached to the application pad; this eliminates the need to combine test sample and indicator reagent prior to use in an assay.
  • the isolation of assay reagents in the application pad also keeps interactive reagents separate and facilitates the manufacturing process.
  • the assay reagents can be introduced in other ways, for example, by immobilization onto the chromatographic strip.
  • the application pad receives the test sample, and the wetting of the application pad by the sample will perform at least two functions. First, it will dissolve or reconstitute a predetermined amount of reagent contained by the pad. Secondly, it will initiate the transfer of both the test sample and the freshly dissolved reagent to the chromatographic material. In some instances, the application pad serves a third function as both an initial mixing site and a reaction site for the test sample and reagent.
  • the reagent containing application pad is dried or lyophilized to increase the shelf-life of the device. Lyophilized application pads were found to produce stronger signals than air dried application pads, and the lyophilized application pads maintained stability for longer periods. The reagents contained in the application pad are rehydrated with the addition of test sample to the pad.
  • the present invention can be further modified by the addition of a filtration means.
  • the filtration means can be a separate material placed above the application pad or between the application pad and the chromatographic material, or the material of the application pad itself can be chosen for its filtration capabilities.
  • the filtration means can include any filter or trapping device used to remove particles above a certain size from the test sample.
  • the filter means can be used to remove red blood cells from a sample of whole blood, such that plasma is the fluid received by the application pad and transferred to the chromatographic material.
  • Such filter means are disclosed by U.S. Pat. No. 4,477,575 and WO Application No. 86/02192, published April 23, 1987.
  • a still further modification of the present invention involves the use of an additional layer or layers of porous material placed between the application pad and the chromatographic material or overlaying the application pad.
  • Such an additional pad or layer can serve as a means to control the rate of flow of the test sample from the application pad to the chromatographic material. Such flow regulation is preferred when an extended incubation period is desired for the reaction of the test sample and the reagent(s) in the application pad.
  • a layer can contain an additional assay reagent(s) which is preferably isolated from the application pad reagents until the test sample is added, or it can serve to prevent unreacted assay reagents from passing to the chromatographic material.
  • a wicking solution preferably a buffered wicking solution
  • a wicking solution generally is not necessary but can be used to improve flow characteristics or adjust the pH of the test sample.
  • the wicking solution typically has a pH range from about 5.5 to about 10.5, and more preferably from about 6.5 to about 9.5. The pH is selected to maintain a significant level of binding affinity between the specific binding members in a binding assay.
  • the pH also must be selected to maintain significant enzyme activity for color development in enzymatic signal production systems.
  • Illustrative buffers include phosphate, carbonate, barbital, diethylamine, tris, 2-amino-2-methyl-l -propanol and the like.
  • the wicking solution and the test sample can be combined prior to contacting the application pad or they can be contacted to the application pad sequentially. Further detailed information relating to the application pads may be found in the prior art.
  • the chromatographic material of the assay device of the present invention can be any suitably absorbent, porous or capillary possessing material through which a solution containing the analyte can be transported by a wicking action.
  • Natural, synthetic, or naturally occurring materials that are synthetically modified, can be used as the chromatographic material including, but not limited to: cellulose materials such as paper, cellulose, and cellulose derivatives such as cellulose acetate and nitrocellulose; fiberglass; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon); porous gels such as silica gel, agarose, dextran, and gelatin; porous fibrous matrixes; starch based materials, such as Sephadex(r) brand cross-linked dextran chains; ceramic materials; films of polyvinyl chloride and combinations of polyvinyl chloride-silica; and the like.
  • the chromatographic material should not interfere with the production of a detectable signal.
  • the chromatographic material should have a reasonable inherent strength, or strength can be provided by means of a supplemental support.
  • a preferred chromatographic material is nitrocellulose. When nitrocellulose is used, however, the material of the application pad should be chosen for its ability to premix the test sample and the first reagent, i.e., fluid-flow through a nitrocellulose membrane is laminar and does not provide the more turbulent flow characteristics which allows the initial mixing of test sample and application pad reagents within the chromatographic material.
  • Porex(r) hydrophilic polyethylene frit or glass fiber filter paper are appropriate application pad materials because they enable the mixing and reaction of the test sample and application pad reagents within the application pad and before transfer to the chromatographic material.
  • a preferred chromatographic material is glass fiber filter paper. Especially preferred for use as the chromatographic material are nitrocellulose laminated strips described in the prior art.
  • the particular dimensions of the chromatographic material will be a matter of convenience, depending upon the size of the test sample involved, the assay protocol, the means for detecting and measuring the signal, and the like. For example, the dimensions may be chosen to regulate the rate of fluid migration as well as the amount of test sample to be imbibed by the chromatographic material.
  • the sample test area and procedural control area can be formed by directly or indirectly attaching their respective capture reagent to the chromatographic material.
  • Direct attachment methods include adsorption, absorption and covalent binding such as by use of (i) a cyanogen halide, e.g., cyanogen bromide or (ii) by use of glutaraldehyde.
  • a cyanogen halide e.g., cyanogen bromide
  • glutaraldehyde glutaraldehyde
  • the means of attaching a reagent to the microparticles encompasses both covalent and non-covalent means, that is adhered, absorbed or adsorbed. It is preferred that capture reagents be attached to the microparticles by covalent means.
  • capture reagents be attached to the microparticles by covalent means.
  • residual and immobilized is meant that the particles, once on the chromato-graphic material, are not capable of substantial movement to positions elsewhere within the material.
  • the particles can be selected by one skilled in the art from any suitable type of particulate material composed of polystyrene, polymethylacrylate, polyacrylamide, polypropylene, latex, polytetrafluoro-ethylene, polyacrylonitrile, polycarbonate, glass or similar materials.
  • the size of the particles is not critical, although generally it is preferred that the average diameter of the particles be smaller than the average pore or capillary size of the chromatographic material.
  • the capture reagent(s) , signal producing component(s) or reagent coated microparticles can be deposited singly or in various combinations on or in the chromatographic material in a variety of configurations to produce different detection or measurement formats.
  • a reagent can be deposited as a discrete situs having an area substantially smaller than that of the entire chromatographic material.
  • the pH indicator dyes can also be selected to respond to the pH of the buffered wicking solution. For example, phenolphthalein changes from clear to intense pink upon contact with a wicking solution having a pH range between 8.0-10.0, which is a common pH range for the assay fluids.
  • kits for carrying out binding assays can comprise the assay device with its incorporated reagents as well as a wicking solution and/or test sample pretreatment reagents as described above.
  • Other assay components known to those skilled in the art, such as buffers, stabilizers, detergents, bacteria inhibiting agents and the like can also be present in the assay device and wicking solution.
  • the migrating test solution or test sample contains both the dissolved indicator reagent from the application pad and the analyte from the test sample. Accordingly, both the indicator reagent and analyte are carried downstream by the advancing liquid front. Moreover, during their migration, the indicator reagent can bind to the analyte to form an indicator reagent/analyte complex. As the wicking liquid transports the indicator reagent/analyte complex through the chromatographic material, the immobilized capture reagent also binds to the analyte to render the indicator reagent/analyte complex immobilized.
  • the indicator reagent/analyte complex is able to advance only as long as capture reagent binding sites on the chromatographic material are already occupied and no longer available for further binding. Consequently, the greater the concentration of analyte in the test sample, the further the distal migration of the indicator reagent/analyte complex through the chromatographic material even beyond the testing region.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des dispositifs améliorés pour l'immunodétection par bandes chromatographiques, qui permettent de déterminer la présence ou la quantité d'un analyte présent dans un échantillon. Les réactifs de marquage entrent en interaction avec les réactifs de capture immobilisés dans une zone de test (22) du substrat (20) de la bande, de façon à générer un image visuellement décelable indiquant le résultat du test. Les réactifs de capture immobilisés responsables de la localisation et de la configuration des images du résultat du test sont appliqués sur la bande à des emplacements sensiblement parallèles à l'écoulement du fluide réactif à l'intérieur de ladite bande.
PCT/US1997/002159 1996-02-23 1997-02-24 Bande chromatographique ayant des zones de detection et de controle orientees parallelement a la direction de l'ecoulement WO1997031268A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20502/97A AU2050297A (en) 1996-02-23 1997-02-24 Chromatographic strip having detection and control zones oriented parallel to the direction of flow

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60477696A 1996-02-23 1996-02-23
US08/604,776 1996-02-23

Publications (1)

Publication Number Publication Date
WO1997031268A1 true WO1997031268A1 (fr) 1997-08-28

Family

ID=24420995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/002159 WO1997031268A1 (fr) 1996-02-23 1997-02-24 Bande chromatographique ayant des zones de detection et de controle orientees parallelement a la direction de l'ecoulement

Country Status (2)

Country Link
AU (1) AU2050297A (fr)
WO (1) WO1997031268A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841569A1 (de) * 1998-05-12 1999-11-25 Virofem Diagnostika Gmbh Indikationsstreifen
DE10108680A1 (de) * 2001-02-23 2002-09-26 Biognostic Ag Affinitätsassay zur schnellen Untersuchung biologischer Materialien
WO2005005986A1 (fr) * 2003-07-09 2005-01-20 Medion Diagnostics Gmbh Dispositif et procede pour realiser simultanement une determination de groupe sanguin, une contre-epreuve serique et un test de detection des anticorps
US7070920B2 (en) 1998-07-14 2006-07-04 Cozart Bioscience Limited Screening arrangment for screening immunoassay tests and agglutination tests
JP2009513939A (ja) * 2003-07-09 2009-04-02 メディオン ダイアグノティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 血液型抗原を同時に決定するための装置及び方法
US7704753B2 (en) * 2005-03-03 2010-04-27 Inverness Medical Switzerland Gmbh Devices and methods for analyte assays with built-in result reporting using recognizable symbols
EP2282206A2 (fr) 2004-02-17 2011-02-09 DST Diagnostische Systeme & Technologien GmbH Méthode et dispositif pour tester plusieurs analytes simultanément avec un control interne
US9182353B2 (en) 2010-07-22 2015-11-10 Hach Company Lab-on-a-chip for alkalinity analysis
US9180449B2 (en) 2012-06-12 2015-11-10 Hach Company Mobile water analysis
USD768872S1 (en) 2012-12-12 2016-10-11 Hach Company Cuvette for a water analysis instrument
WO2017066645A1 (fr) 2015-10-15 2017-04-20 Inbios International, Inc. Systèmes de dosage à écoulement latéral multiplexé et leurs procédés d'utilisation
CN111487230A (zh) * 2020-04-20 2020-08-04 中国农业科学院烟草研究所 一种青枯病菌检测装置
US11320432B2 (en) * 2012-05-14 2022-05-03 Lawrence Livermore National Security, Llc System with buffer for lateral flow on a porous membrane

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916056A (en) * 1986-02-18 1990-04-10 Abbott Laboratories Solid-phase analytical device and method for using same
US5075078A (en) * 1989-10-05 1991-12-24 Abbott Laboratories Self-performing immunochromatographic device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916056A (en) * 1986-02-18 1990-04-10 Abbott Laboratories Solid-phase analytical device and method for using same
US5075078A (en) * 1989-10-05 1991-12-24 Abbott Laboratories Self-performing immunochromatographic device

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841569A1 (de) * 1998-05-12 1999-11-25 Virofem Diagnostika Gmbh Indikationsstreifen
DE19841569C2 (de) * 1998-05-12 2000-03-09 Virofem Diagnostika Gmbh Indikationsstreifen
US7803633B2 (en) 1998-07-14 2010-09-28 Cozart Bioscience Limited Screening arrangement for screening immunoassay tests and agglutination tests
US7070920B2 (en) 1998-07-14 2006-07-04 Cozart Bioscience Limited Screening arrangment for screening immunoassay tests and agglutination tests
DE10108680A1 (de) * 2001-02-23 2002-09-26 Biognostic Ag Affinitätsassay zur schnellen Untersuchung biologischer Materialien
JP2009513938A (ja) * 2003-07-09 2009-04-02 メディオン ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 血液型決定、血清クロスチェック及び抗体検索試験を同時に行うための装置及び方法
JP2009513939A (ja) * 2003-07-09 2009-04-02 メディオン ダイアグノティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 血液型抗原を同時に決定するための装置及び方法
AU2004256206B2 (en) * 2003-07-09 2010-03-04 Grifols Diagnostics Solutions Inc Device and method for simultaneous carrying out of blood group determination, serum cross-check and antibody detection test
DE10330981B4 (de) * 2003-07-09 2010-04-01 Medion Diagnostics Ag Vorrichtung und Verfahren zur simultanen Durchführung von Blutgruppenbestimmung, Serumgegenprobe und Antikörpersuch-Test
US7745228B2 (en) 2003-07-09 2010-06-29 Medion Diagnostics Ag Device for simultaneously carrying out blood group determination, serum cross-check and antibody detection test
AU2004256210B2 (en) * 2003-07-09 2010-07-01 Grifols Diagnostics Solutions Inc Device and method for simultaneously identifying blood group antigens
WO2005005986A1 (fr) * 2003-07-09 2005-01-20 Medion Diagnostics Gmbh Dispositif et procede pour realiser simultanement une determination de groupe sanguin, une contre-epreuve serique et un test de detection des anticorps
AU2004256210B9 (en) * 2003-07-09 2011-01-27 Grifols Diagnostics Solutions Inc Device and method for simultaneously identifying blood group antigens
US8053226B2 (en) 2003-07-09 2011-11-08 Medion Diagnostics Ag Device and method for simultaneously identifying blood group antigens
EP2282206A2 (fr) 2004-02-17 2011-02-09 DST Diagnostische Systeme & Technologien GmbH Méthode et dispositif pour tester plusieurs analytes simultanément avec un control interne
US7704753B2 (en) * 2005-03-03 2010-04-27 Inverness Medical Switzerland Gmbh Devices and methods for analyte assays with built-in result reporting using recognizable symbols
US9182353B2 (en) 2010-07-22 2015-11-10 Hach Company Lab-on-a-chip for alkalinity analysis
US11320432B2 (en) * 2012-05-14 2022-05-03 Lawrence Livermore National Security, Llc System with buffer for lateral flow on a porous membrane
US11933782B2 (en) 2012-05-14 2024-03-19 Lawrence Livermore National Security, Llc System with liquid and solid media for target binding
US9180449B2 (en) 2012-06-12 2015-11-10 Hach Company Mobile water analysis
USD768872S1 (en) 2012-12-12 2016-10-11 Hach Company Cuvette for a water analysis instrument
WO2017066645A1 (fr) 2015-10-15 2017-04-20 Inbios International, Inc. Systèmes de dosage à écoulement latéral multiplexé et leurs procédés d'utilisation
EP3362180A4 (fr) * 2015-10-15 2019-06-12 Inbios International Inc. Systèmes de dosage à écoulement latéral multiplexé et leurs procédés d'utilisation
US10996221B2 (en) 2015-10-15 2021-05-04 Inbios International, Inc. Multiplexed lateral flow assay systems and methods for their use
AU2016340125B2 (en) * 2015-10-15 2021-12-09 Inbios International, Inc. Disabled Multiplexed lateral flow assay systems and methods for their use
CN111487230A (zh) * 2020-04-20 2020-08-04 中国农业科学院烟草研究所 一种青枯病菌检测装置

Also Published As

Publication number Publication date
AU2050297A (en) 1997-09-10

Similar Documents

Publication Publication Date Title
US5075078A (en) Self-performing immunochromatographic device
US5780308A (en) Calibration reagents for semiquanitative binding assays and devices
US5308775A (en) Assay devices for concurrently detecting an analyte and confirming the test result
EP0323605B1 (fr) Appareil et méthodes de test chromatographique de liaison
US6686170B1 (en) Assay devices with mobile control reagents
EP0349215B1 (fr) Méthode et dispositif pour détection
EP0462376B1 (fr) Essais faisant intervenir de liaisons avec récupération de conjugue
US6924153B1 (en) Quantitative lateral flow assays and devices
CA1309654C (fr) Essai sur membranes utilisant la technique de l'application dirigee de l'echantillon
US6767710B2 (en) Prewetting stop flow test strip
EP0389003B1 (fr) Dispositif analytique en phase solide et procédé pour son utilisation
EP0941468B1 (fr) Dispositif hybride d'immunochromatographie en une etape et procede d'utilisation
US8722426B2 (en) Devices for the detection of multiple analytes in a sample
JP2537873B2 (ja) 金ゾル試薬の調整方法
US20020085958A1 (en) Apparatus for pretreating a sample containing an analyte
WO2007097917A1 (fr) Appareil d'immunodosage à combinaison de flux vertical et latéral
WO1997031268A1 (fr) Bande chromatographique ayant des zones de detection et de controle orientees parallelement a la direction de l'ecoulement
WO1994006940A1 (fr) Dispositifs de titrage a bandes-test multiples

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97530210

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase